Protein Degradation: Technologies, Drug Programs, and Services
Targeted Protein Degradation / PROTAC
This guide organizes companies and updates by PROTACs, molecular glue degraders, and other degradation approaches. Use the target, lead program, and development stage to distinguish mechanistic research, clinical development, and services offered to clients.
Questions to ask first
- Which degradation approach does the lead program use, and what target and mechanism have been disclosed?
- In which experimental systems or patient populations were degradation, selectivity, and disease-related outcomes observed?
- Does the company develop its own pipeline or provide discovery, testing, delivery, or CMC services, and is the deliverable clearly defined?
Key terms
- PROTAC
- The heterobifunctional degrader category in this map, classified separately from molecular glue degraders and other approaches.
- Molecular glue degrader
- A distinct degradation category in this map, rather than a label applied to every PROTAC program.
- CMC services
- Development work addressing chemistry, manufacturing, and controls, assessed separately from drug discovery and clinical efficacy.
Evidence and scope
Technology categories support navigation; they are not ratings of efficacy or technical superiority. Cellular degradation does not establish clinical benefit, and starting a trial does not establish a positive outcome. Verify platform capabilities separately from the progress of individual drug programs.
Technology snapshot: 2026-10-31 · Research methods
